MBS-105(MBS-105) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式-

作用机制-

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Microbion Corp.

在研机构-

非在研机构

Microbion Corp.

权益机构-

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 MBS-105 相关的临床结果

登录后查看更多信息

100 项与 MBS-105 相关的转化医学

登录后查看更多信息

100 项与 MBS-105 相关的专利（医药）

登录后查看更多信息

1

项与 MBS-105 相关的文献（医药）

1982-05-01·Biochemical Pharmacology2区 · 医学

Immunopurification of cytochrome P-448 from microsomal fractions of rabbit liver with retention of metabolic activity

2区 · 医学

Article

作者: M.B. Slade ; D.S. Davies ; K.M. Lewis ; A.R. Boobis

A mouse monoclonal antibody, MBS 105, raised against rabbit liver microsome cytochrome P-448 (I), had no effect on the activity of the benzo[a]pyrene hydroxylase system from rabbit liver microsomes.The antibody was covalently bound to CH-activated Sepharose and incubated with rabbit cholate-solubilized liver microsomal fractions.A protein of mol. weight 55,000 was adsorbed, but could not be subsequently eluted from the gel.A reconstituted system comprising immobilized cytochrome P-448, NADPH-cytochrome P-450 reductase, and dilauryl-α-lecithin was capable of oxidizing benzo[a]pyrene.

100 项与 MBS-105 相关的药物交易

登录后查看更多信息